Not logged in Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition Moedt, Erik; Koshino, Akihiko; Jongs, Niels; Ju, Wenjun; Nair, Viji; Kretzler, Matthias; Hansen, Michael K.; Arnott, Clare G.; Wheeler, David C.; Rossing, Peter; Coca, Steven G.; Hammarstedt, Ann; Greasley, Peter J.; Bjornstad, Petter; Bakker, Stephan J. L.; Heerspink, Hiddo J. L. Share Save
G2-PASE: A Novel, Rapid, and Reliable Measure of Plaque Psoriasis Severity Gulliver, Wayne P.; Langholff, Wayne; Guenther, Lyn; Prajapati, Vimal H.; Ringuet, Julien; Yadav, Om Prakash; Gulliver, Susanne R.; Fakharzadeh, Steve; Lafferty, Kim Parnell; Abbarin, Nastaran; Gniadecki, Robert Share Save
Blood-based biomarkers of gut barrier integrity associate with disease activity and future disease progression in inflammatory bowel disease Geertsema, S.; Bourgonje, A. R.; Veenstra, F.; Gacesa, R.; Fagundes, R. R.; Spekhorst, L.; Hu, S.; de Jong, S.; Jansen, B. H.; Holstein, H.; Ruane, D.; Kannan, A. K.; Weersma, R. K.; van Goor, H.; Dijkstra, G.; Faber, K. N. Share Save
Share Save
Share Save
Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study Fan, Fenling; Sun, Luying; Yang, Zhenwen; Wang, Lan; Wang, Qiguang; Li, Jiang; Gu, Hong; Xie, Weiping; Zhang, Nuofu; Bin, Jia; Rofael, Hany; Friberg, Michael; Hauser, Jakob A. Share Save
Biosynthesis and structure assignment of a hydroxylated metabolite of the orexin-1 receptor antagonist JNJ-61393215 Song, Fengbin; Chen, Jie; Dallas, Shannon; Lam, Wing; Lim, Heng-Keang; Zhou, Ronghui; Kokubun, Tetsuo; Phipps, Richard; Steele, Jonathan; Salter, Rhys Share Save
Share Save
Share Save
Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study Bressler, B.; Peyrin-Biroulet, L.; Afif, W.; Samaan, M. A.; Wei, S. C.; Yarandi, S.; Germinaro, M.; Mistry, P.; Han, C.; Allegretti, J. R.; Lichtenstein, G. R. Share Save
Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results through Week 48 from the phase 3 GRAVITI study Hart, A.; Panaccione, R.; Steinwurz, F.; Danese, S.; Hisamatsu, T.; Cao, Q.; Olurinde, M.; Vetter, M. L.; Yang, Z.; Wang, Y.; Johanns, J.; Terry, N. A.; Sands, B. E.; D'Haens, G. Share Save
Early disease efficacy of guselkumab therapy in biologic-naive patients with moderately to severely active Crohn's disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies Afzali, A.; Rubin, D. T.; Danese, S.; Rayyan, Y.; Chen, M.; Terry, N. A.; Salese, L.; Van Rampelbergh, R.; Yee, J.; Gomez, M.; Wan, K. Y. Y.; Yang, Z.; Sands, B. E.; D'Haens, G. Share Save
Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn's disease: Phase 3 GRAVITI study Sands, B.; Danese, S.; Cao, Q.; Steinwurz, F.; Kierkus, J.; Han, C.; Olurinde, M.; Yang, Z.; Merrall, E.; Terry, N. A.; Hart, A. Share Save
Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results at Week 12 from the phase 3 GRAVITI study D'Haens, G.; Hisamatsu, T.; Steinwurz, F.; Hart, A.; Liu, W.; Olurinde, M.; Ngqawa, P.; Yang, Z.; Merrall, E.; Terry, N. A.; Sands, B. E.; Panaccione, R. Share Save
Comparison of pharmacodynamic and mechanistic response of guselkumab intravenous and subcutaneous induction in moderately to severely active Crohn's disease: molecular analysis of the GRAVITI and GALAXI Phase 3 studies Richards, D.; Patel, R.; Sohn, K.; Hart, A.; Lee, T.; Liu, J.; Sisk, C.; Olurinde, M.; Terry, N.; Mcrae, B.; Reinisch, W.; Feagan, B.; Steinwurz, F.; Panaccione, R.; D'Haens, G.; Branigan, P. Share Save
Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn's disease: Phase 3 GRAVITI study results through week 48 Hart, A.; Panaccione, R.; Steinwurz, F.; Cao, Q.; Hisamatsu, T.; Nancey, S.; Olurinde, M.; Yang, Z.; Merrall, E.; Terry, N. A.; Sands, B. E. Share Save
Guselkumab efficacy and safety in East Asian participants with moderate to severely active Ulcerative Colitis: Subgroup analysis of the Phase 2b/3 QUASAR induction and maintenance studies Chen, B.; Ye, B. D.; Cao, Q.; Hirai, F.; Saruta, M.; Chen, M.; Pelak, S.; Shipitofsky, N.; Wahking, B.; Zhuo, J.; Hisamatsu, T. Share Save
Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn's disease: Results from the phase 3 GRAVITI study Hart, A.; Hisamatsu, T.; Steinwurz, F.; D'Haens, G.; Liu, W.; Olurinde, M.; Ngqawa, P.; Yang, Z.; Merrall, E.; Terry, N. A.; Panaccione, R.; Sands, B. E. Share Save
DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis Hart, A.; Sridhar, S.; Venkat, S.; Huang, K. H. G.; Yarandi, S.; Germinaro, M.; Vetter, M. L.; Rubin, D. T.; Dignass, A.; Cua, D.; Freeman, T.; Waterworth, D.; Mcrae, B.; Verstockt, B.; Branigan, P. Share Save
Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials De Greef, E.; Kosaras, E.; Beres, N.; Cohen, S.; Conklin, L.; Strauss, R.; Godwin, B.; Damaraju, L.; Zhang, R.; Volger, S.; Kim, L.; Van Limbergen, E. Share Save
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
